PMID- 15550477
OWN - NLM
STAT- MEDLINE
DCOM- 20050207
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 51
IP  - 1
DP  - 2005 Jan
TI  - N-terminal pro-B-type natriuretic peptide as an indicator of possible 
      cardiovascular disease in severely obese individuals: comparison with patients in 
      different stages of heart failure.
PG  - 138-43
AB  - BACKGROUND: Mild stages of heart failure might be difficult to diagnose in 
      severely obese individuals with a body mass index (BMI) >40 kg/m(2). Measurement 
      of the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) is 
      feasible for detecting cardiac impairment. The aims of our study were to measure 
      NT-proBNP in plasma of severely obese patients and to compare the results with 
      results for patients in different stages of manifest cardiac dysfunction. 
      METHODS: In 61 severely obese individuals (median BMI, 43.2 kg/m(2)) and 96 
      nonobese patients with existing heart failure [classified into New York Heart 
      Association (NYHA) classes I-IV], NT-proBNP was measured in the fasting 
      condition. A medical history, physical examination, electrocardiography, blood 
      chemistry, and chest x-ray were performed in the obese group. In addition, 
      echocardiography was performed in the NYHA group. RESULTS: In obese individuals, 
      NT-proBNP was increased to a median of 356 (interquartile range, 221-458) pmol/L 
      [854 (530-1099) ng/L] and was comparable (P >0.05) to the median value for NYHA I 
      patients 289 (258-451) pmol/L [694 (619-1082) ng/L], but was significantly 
      lower than in the other NYHA groups (P <0.001 for each). CONCLUSION: The 
      prognostic relevance of increased NT-proBNP for risk of developing cardiac 
      insufficiency in severely obese patients needs to be further evaluated.
FAU - Hermann-Arnhof, Katharina-Maria
AU  - Hermann-Arnhof KM
AD  - Department for Clinical and Chemical Laboratory Diagnostic, Hospital Lainz, 1130 
      Vienna, Austria. katharina.hermann@wienkav.at
FAU - Hanusch-Enserer, Ursula
AU  - Hanusch-Enserer U
FAU - Kaestenbauer, Thomas
AU  - Kaestenbauer T
FAU - Publig, Thomas
AU  - Publig T
FAU - Dunky, Attila
AU  - Dunky A
FAU - Rosen, Harald R
AU  - Rosen HR
FAU - Prager, Rudolf
AU  - Prager R
FAU - Koller, Ursula
AU  - Koller U
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20041118
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Biomarkers)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Precursors)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Cross-Sectional Studies
MH  - Female
MH  - Heart Failure/*blood/diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain
MH  - Nerve Tissue Proteins/*blood
MH  - Obesity/*blood
MH  - Peptide Fragments/*blood
MH  - Protein Precursors/*blood
EDAT- 2004/11/20 09:00
MHDA- 2005/02/08 09:00
CRDT- 2004/11/20 09:00
PHST- 2004/11/20 09:00 [pubmed]
PHST- 2005/02/08 09:00 [medline]
PHST- 2004/11/20 09:00 [entrez]
AID - clinchem.2004.035923 [pii]
AID - 10.1373/clinchem.2004.035923 [doi]
PST - ppublish
SO  - Clin Chem. 2005 Jan;51(1):138-43. doi: 10.1373/clinchem.2004.035923. Epub 2004 
      Nov 18.